Summary & Overview
HCPCS Q4113: Graftjacket Xpress Injectable, 1 cc
HCPCS Level II code Q4113 denotes Graftjacket xpress, an injectable biologic graft supplied in a 1 cc unit. As an HCPCS Level II product code, Q4113 is used on professional and facility claims to identify a specific injectable biologic graft material used in soft-tissue repair and augmentation. Nationally, accurate coding for biologic graft products affects coverage determinations, inventory tracking, and payment processes across public and commercial payers. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what this code represents clinically, the typical sites of service where it is used, and which major payers are included in coverage comparisons. The publication summarizes coding context and highlights sections on payer coverage patterns, billing benchmarks, and any relevant policy updates or prior authorization considerations when available. Where specific input data is missing, the report indicates that those items are not available in the input. This briefing is intended to inform billing staff, practice managers, and policy analysts about the role of HCPCS Level II code Q4113 in claims and reimbursement workflows at a national level.
Billing Code Overview
HCPCS Level II code Q4113 represents Graftjacket xpress, injectable, 1 cc, a biologic graft material supplied in an injectable 1 cc formulation. The service type is injectable biologic graft placement, intended for use in soft tissue repair or augmentation. The typical site of service is outpatient clinic or ambulatory surgical setting, where injectable graft materials are administered by clinicians familiar with biologic wound and soft-tissue repair techniques.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic, non-healing soft-tissue wound (for example, a diabetic foot ulcer or a surgical dehisced wound) presenting to an outpatient wound care clinic or hospital-based wound center. After initial evaluation, conservative measures (debridement, offloading, infection control, and advanced dressings) have not achieved adequate progress. The clinician selects an injectable human-derived extracellular matrix product indicated to support wound healing and tissue regeneration. The procedure is performed in a procedure room, minor procedure suite, ambulatory surgery center, or hospital outpatient department. The workflow includes wound assessment and measurement, sharp or enzymatic debridement as needed, cleansing and hemostasis, preparation and reconstitution of the Q4113 product (Graftjacket xpress, injectable, 1 cc), and periwound infiltration or direct application of the injectable graft material into the wound bed. Local anesthesia or procedural sedation may be used depending on wound sensitivity and patient factors. Post-procedure documentation includes product name and lot number, quantity used in cc, exact wound location and dimensions, method of application, specimens if sent, and follow-up wound care plan. Typical clinical team members include a wound care physician (often a vascular surgeon, plastic surgeon, or podiatrist), nursing staff, and medical assistants. Billing includes the HCPCS Level II code Q4113 with appropriate modifiers to reflect bilateral procedures, reduced services, or a significant procedural service when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|